Radiation Oncology最新文献

{"title":"Moderately hypofractionated online adaptive radiotherapy (SWIFT-1) in cervical cancer patients: study protocol for a multi-centered, open-label, two-arm, phase III, randomized controlled study.","authors":"Zheng Zeng, Yining Chen, Jie Qiu, Bo Yang, Zhiqun Wang, Xiangyin Meng, Yuliang Sun, Junfang Yan, Ke Hu, Fuquan Zhang","doi":"10.1186/s13014-025-02688-7","DOIUrl":"10.1186/s13014-025-02688-7","url":null,"abstract":"<p><strong>Background: </strong>External beam radiotherapy (EBRT) is an essential component of standard treatment for locally advanced cervical cancer. Moderately hypofractionated radiotherapy (MHRT) offers the potential to reduce treatment burden while compromising efficacy. Although various studies have investigated the safety and efficacy of MHRT, high-quality evidence remains inadequate. The lack of integration of modern radiotherapy techniques in many existing studies may lead to an overestimation of MHRT-associated toxicity.</p><p><strong>Methods: </strong>This prospective, multi-center, randomized controlled, non-inferiority phase III trial aims to evaluate the non-inferiority of moderately hypofractionated online adaptive radiotherapy (oART) compared to conventional fractionated radiotherapy (CFRT). A total of 440 participants will be enrolled and randomly assigned in a 1:1 ratio to either the MHRT or CFRT group. Both groups will receive concurrent chemoradiotherapy, and a subset of eligible patients will undergo immunotherapy. The prescribed EBRT dose for the MHRT group will be 43.35 Gy in 17 fractions, with a simultaneous integrated boost of 54.4 Gy in 17 fractions to positive lymph nodes. The CFRT group will receive 45 Gy in 25 fractions, with a simultaneous integrated boost of 60 Gy in 25 fractions to positive lymph nodes. The primary endpoint will be 3-year progression-free survival. Secondary endpoints will include the complete response rate, tumor regression following EBRT, overall survival, locoregional progression-free survival, metastasis-free survival, cervical cancer-specific survival, acute and late toxicity, and quality of life.</p><p><strong>Discussion: </strong>This randomized controlled trial will prospectively investigate whether MHRT is non-inferior to conventional fractionation in terms of efficacy and safety. Furthermore, the trial will evaluate the potential of moderately hypofractionated oART as a clinically viable alternative to CFRT for the treatment of locally advanced cervical cancer.</p><p><strong>Trial registration: </strong>This trial was registered at ClincalTrials.gov (NCT06641635) on October 12, 2024.</p>","PeriodicalId":49639,"journal":{"name":"Radiation Oncology","volume":"20 1","pages":"112"},"PeriodicalIF":3.3,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic radiotherapy with Gamma Master System^® for palliation of hepatocellular carcinoma in patients with liver cirrhosis.","authors":"Bin Qiu, Fang Fang, Peng Zhen, Junjie Wang","doi":"10.1186/s13014-025-02683-y","DOIUrl":"10.1186/s13014-025-02683-y","url":null,"abstract":"<p><strong>Background: </strong>Stereotactic radiotherapy with Gamma Master System^® delivered for portal vein tumor thrombosis (PVTT) located in the main portal vein is previously exploited. The study aimed to evaluate the efficacy and safety of stereotactic radiotherapy with Gamma Master System^® for palliation of hepatocellular carcinoma in patients with liver cirrhosis.</p><p><strong>Methods: </strong>From March 2014 to March 2024, 96 patients (mean age, 59.7 ± 9.0, range, 39-87 years; 86, 89.6% males) with hepatocellular carcinoma and liver cirrhosis underwent stereotactic radiotherapy with Gamma Master System^® in our institute were retrospectively reviewed.</p><p><strong>Results: </strong>Of the 96 patients, 80 (83.3%) patients demonstrated disease control, defined as 8 (8.3%) complete response, 63 (65.6%) partial response, and 9 (9.4%) stable disease. Median progression-free survival (PFS) was 6.0 ± 0.6 months [interquartile range (IQR), 3-14 months], with a 1-year PFS rate of 26.9%, the median overall survival (OS) reached 14.0 ± 1.3 months (IQR, 8-27 months), with an estimated 1-year survival rate of 61.8%. Of the 61 painful patients, 59 (96.7%) reported pain relief. The AFP decreased from 1070.5 ± 364.4 ng/ml before radiotherapy to 688.6 ± 301.5 ng/ml after radiotherapy (p = 0.081). Child-Pugh classification (A 74 cases, 77.1%, and B 22 cases, 22.6%) before radiotherapy was similar to that (A 74 cases, 77.1%, and B 22 cases, 22.6%) after radiotherapy, with 1 case changed from A to B and 1 case changed from B to A. Only one patient experienced grade 4 hematologic toxicity, which was managed with transfusion. Immune-related dermatitis occurred in 2 (7.1%) of the 28 patients combined with immunotherapy/targeted therapy. No other major complications were observed.</p><p><strong>Conclusions: </strong>Stereotactic radiotherapy with Gamma Master System^® for palliation appears effective and safe in liver cirrhosis patients with hepatocellular carcinoma yielding a high rate of tumor response. This treatment may provide a valuable option for pain relief. Further study is warranted.</p>","PeriodicalId":49639,"journal":{"name":"Radiation Oncology","volume":"20 1","pages":"110"},"PeriodicalIF":3.3,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12265294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144644004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research trends of selective internal radiation therapy for liver cancer: a bibliometric analysis.","authors":"Mingkun Liu, Tong Xia, Qianqian Xu, Yanfeng Liu","doi":"10.1186/s13014-025-02690-z","DOIUrl":"10.1186/s13014-025-02690-z","url":null,"abstract":"<p><strong>Background: </strong>Liver cancer is a major contributor to cancer-related mortality. Selective internal radiation therapy (SIRT) for liver cancer has garnered increasing attention. This study aims to comprehensively describe the current status, hotspots and trends of SIRT.</p><p><strong>Methods: </strong>Publications from January 1, 1994, to May 31, 2024, were retrieved from the Web of Science Core Collection. CiteSpace, VOSviewer, the Bibliometrix package from R software, and an online analytical platform were used for knowledge mapping analysis and visualization.</p><p><strong>Results: </strong>A total of 2046 publications were retrieved from the Web of Science Core Collection. The number of publications related to SIRT for liver cancer has been continuously increasing, particularly since 2005. The United States led in publications, and a strong collaboration network was observed among countries, particularly within Europe and America. The Northwestern University had the highest number of publications in the field of SIRT. Co-citation analysis identified \"predictive dosimetry\" and \"atezolizumab\" as current focal points within the field. High-frequency keywords include \"transarterial radioembolization\", \"Y90 microspheres\", \"hepatocellular carcinoma\", while recent citation bursts are predominantly centered on \"lung shunt fraction,\" \"tumor dose,\" \"systemic therapy,\" \"radiation segmentectomy,\" \"Holmium-166,\" etc. CONCLUSION: As a local treatment, SIRT exhibits significant promise for its future role in the management of hepatic malignancies. Numerous studies on SIRT are actively in progress. Our study suggests that radiation segmentectomy may emerge as an important treatment in the future. Moreover, personalized dosimetry, the combination of SIRT with immunotherapy, and the development of novel radioactive agents are identified as pivotal areas for future research.</p>","PeriodicalId":49639,"journal":{"name":"Radiation Oncology","volume":"20 1","pages":"109"},"PeriodicalIF":3.3,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of health-related quality-of-life results after lung stereotactic body radiotherapy using dose-volume parameters from functional mapping on Gallium-68 perfusion PET/CT.","authors":"François Lucia, Jacques Lamour, Margaux Geier, Vincent Bourbonne, Fanny Pinot, Malik Nebbache, Frédérique Blanc-Béguin, Simon Hennebicq, Maëlle Mauguen, Kevin Kerleguer, Ulrike Schick, Olivier Pradier, Grégoire Le Gal, Pierre-Yves Salaun, David Bourhis, Pierre-Yves Le Roux","doi":"10.1186/s13014-025-02685-w","DOIUrl":"10.1186/s13014-025-02685-w","url":null,"abstract":"<p><strong>Background: </strong>The PEGASUS trial was the first study to evaluate and demonstrate the benefits of ⁶⁸Ga-perfusion PET/CT in the lung stereotactic body radiotherapy (SBRT) planning process in preserving functional lung volumes while respecting target volume coverage and doses to other organs at risk. Here we report the prespecified exploratory endpoint of SBRT on health-related quality of life (HRQoL).</p><p><strong>Methods: </strong>In this single-center prospective study, we recruited patients planned to be treated in our radiotherapy department with SBRT for primary or secondary lung tumors. Patient-reported outcomes were assessed at the first visit, 1 month, 3 months and every 3 months until 12 months after SBRT using the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30), the EORTC Quality of Life Questionnaire Lung Cancer 13 items (QLQ-LC13), and the European Quality of Life 5 Dimensions-5 Level (EQ-5D-5 L) questionnaire. The key exploratory HRQoL endpoints (analyzed for all patients who completed at least QLQ-C30 at least one time point after SBRT) were baseline-to-early change (between 1 month and 3 month) and baseline-to-late change (between 6 month and 12 month) in the QLQ-C30 global health status (GHS)/quality-of-life (QoL) score and in the deterioration of the dyspnea (patient-reported lung toxicity). Explorative analysis of the impact of baseline HRQoL, patient- and SBRT-related characteristics, including PET perfusion-based functional parameters, on the change in HRQoL from baseline was analyzed using univariate analysis.</p><p><strong>Results: </strong>Of the 60 patients included, 39 were analyzable as early-onset and 22 as late-onset. Thirteen (33%) and 7 (32%) patients had a deterioration of QoL. In univariate analysis, maximal dose to the heart, doses to the functional lung volume and pulmonary functional test parameters were significantly associated with the early deterioration of HRQoL. Only doses to the functional lung volume were significantly associated with the late deterioration of HRQoL.</p><p><strong>Conclusion: </strong>In our study, increased radiation doses in functional lung volume PET bases dose parameters were significantly associated with a decrease of HRQoL unlike anatomic lung parameters. Functional lung avoidance planning guided by perfusion PET/CT may be a simple and noninvasive method to improve HRQoL in patients treated with lung SBRT.</p>","PeriodicalId":49639,"journal":{"name":"Radiation Oncology","volume":"20 1","pages":"108"},"PeriodicalIF":3.3,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12243402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simultaneous concurrent chemoradiotherapy and esophagectomy for synchronous head and neck and esophageal squamous cell carcinoma: a retrospective review.","authors":"Yu-Ming Huang, Yi-Shing Leu, Jehn-Chuan Lee, Chao-Hung Chen, Hung-Chang Liu, Chih-Hao Chen, Huan-Chau Lin, Nai-Wen Su, Wen-Chien Huang, Yu-Jen Chen","doi":"10.1186/s13014-025-02681-0","DOIUrl":"10.1186/s13014-025-02681-0","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to assess the clinical outcomes and prognostic factors of patients with synchronous head and neck squamous cell carcinoma (HNSCC) and esophageal squamous cell carcinoma (ESCC) who underwent simultaneous concurrent chemoradiotherapy (CCRT) and esophagectomy.</p><p><strong>Methods: </strong>Thirty-one patients who underwent simultaneous CCRT for synchronous HNSCC and ESCC were retrospectively reviewed. The treatment strategy involved simultaneous definitive CCRT at 70 Gy/35 fractions for HNSCC and neoadjuvant CCRT at 48 Gy/24 fractions for ESCC. Esophagectomy was evaluated 4-5 weeks after neoadjuvant CCRT. The radiotherapy plan utilized a simultaneously integrated boost technique at 4-5 dose levels. Patients received weekly platinum chemotherapy during CCRT. Patient characteristics, treatment responses, and survival rates were analyzed. Survival analysis was conducted using the Kaplan-Meier method and Cox regression analyses.</p><p><strong>Results: </strong>All the patients completed CCRT at the planned doses and radiation fields with a good tolerance profile. The 1- and 2-year survival rates were 62.9% and 34.4%, respectively. Performance status (PS), ESCC tumor location, HNSCC clinical stage, and clinical responses of HNSCC and ESCC, both individually and combined, were significantly associated with prognosis. PS and the clinical response of ESCC were significant predictors of overall survival. Adverse effects were manageable, with up to eleven patients (35.5%) developing grade 3/4 neutropenia. No treatment-related mortality was noted.</p><p><strong>Conclusions: </strong>The treatment strategy using simultaneous definitive CCRT for HNSCC and neoadjuvant CCRT for ESCC followed by esophagectomy for synchronous HNSCC and ESCC is effective and well-tolerated. PS and clinical response of ESCC are significant prognostic factors for this treatment strategy.</p>","PeriodicalId":49639,"journal":{"name":"Radiation Oncology","volume":"20 1","pages":"107"},"PeriodicalIF":3.3,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12243128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prescription dose and optimisation strategies in MR-guided online adaptive radiotherapy for kidney tumours: a two-step planning analysis.","authors":"Takaya Yamamoto, Noriyoshi Takahashi, Shohei Tanaka, Rei Umezawa, Yu Suzuki, Keita Kishida, So Omata, Kazuya Takeda, Hinako Harada, Kiyokazu Sato, Noriyuki Kadoya, Keiichi Jingu","doi":"10.1186/s13014-025-02682-z","DOIUrl":"10.1186/s13014-025-02682-z","url":null,"abstract":"<p><strong>Background: </strong>Stereotactic radiotherapy (SRT) for kidney cancer, particularly when tumours are situated near critical organs-at-risk (OARs), presents significant challenges in achieving optimal dose delivery. MR-guided online adaptive radiotherapy (MRgoART) offers a promising solution by allowing real-time anatomical modification and plan reoptimisation. However, the ideal strategy for prescription dose selection and reoptimisation remains unclear.</p><p><strong>Methods: </strong>This single-centre planning study evaluated kidney tumours located within 1 cm of gastrointestinal OARs. In Step 1, prescription doses for MRgoART were compared: the target dose (26 Gy) versus the planned dose (adjusted during pre-treatment planning to satisfy OAR constraints). In Step 2, two optimisation strategies were assessed: (1) covering 99% of the planning target volume (PTV) with the prescription dose (99%_xGy_Plan) and (2) delivering the full target dose with acceptable partial PTV coverage accepting dose heterogeneity (26Gy_x%_Plan), both respecting OAR constraints. Dose-volume parameters and blinded expert preferences were evaluated.</p><p><strong>Results: </strong>Of 22 patients assessed, 14 patients with 18 tumours met the inclusion criteria. Among these, 36 MRgoART plans for 12 tumours were analysed in Step 1. Reoptimisation using the target dose resulted in significantly higher mean tumour doses, improved dose gradients, and PTV coverage metrics compared to reoptimisation based on the planned dose. In Step 2, 54 plans were assessed. Although the 26Gy_x%_Plan demonstrated superior mean tumour and PTV dose, it exhibited lower conformity. Radiation oncologists preferred the 26Gy_x%_Plan in 48% of cases, following 26% deemed almost equal, indicating its clinical advantage.</p><p><strong>Conclusion: </strong>For kidney tumours adjacent to gastrointestinal OARs, MRgoART planning should favour reoptimisation based on the target dose. A high-dose strategy with partial PTV coverage (26Gy_x%_Plan) was generally preferred by radiation oncologists, balancing therapeutic effectiveness with OAR protection.</p>","PeriodicalId":49639,"journal":{"name":"Radiation Oncology","volume":"20 1","pages":"106"},"PeriodicalIF":3.3,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12228998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements in the application of MRI radiomics in meningioma.","authors":"Dengpan Song, Ruoyu Cai, Yuanhao Lou, Kaiyuan Zhang, Dingkang Xu, Dongming Yan, Fuyou Guo","doi":"10.1186/s13014-025-02679-8","DOIUrl":"10.1186/s13014-025-02679-8","url":null,"abstract":"<p><p>Meningiomas are among the most common intracranial tumors, and challenges still remain in terms of tumor classification, treatment, and management. With the popularization of artificial intelligence technology, radiomics has been further developed and more extensively applied in the study of meningiomas. This objective and quantitative technique has played an important role in the identification, classification, grading, pathology, treatment, and prognosis of meningiomas, although new problems have also emerged. This review examines the application of magnetic resonance imaging (MRI) techniques in meningioma research. A database search was conducted for articles published between November 2017 and April 2025, with a total of 87 studies included after screening. These studies were summarized in detail, and the risk of bias and the certainty of the evidence were assessed using the Quality Assessment of Diagnostic Accuracy Studies version 2 (QUADAS-2) and radiomics quality scores (RQS). All the studies were retrospective, with most being single-center studies. Contrast-enhanced T1-weighted imaging (T1C) and T2-weighted imaging (T2WI) are the most commonly used MRI sequences. Current research focuses on five topics, namely, differentiation, grade and subtypes, molecular pathology, biological behavior, treatment, and complications, with 14, 32, 14, 12, and 19 studies addressing these topics (some of which are multiple topics). Combined imaging features with clinical or pathological features often outperform traditional clinical models. Most studies show a low to moderate risk of bias. Large, prospective, multicenter studies are needed to validate the performance of radiomic models in diverse patient populations before their clinical implementation can be considered.</p>","PeriodicalId":49639,"journal":{"name":"Radiation Oncology","volume":"20 1","pages":"105"},"PeriodicalIF":3.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12210666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144545834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of chemoradiotherapy for bladder cancer on pre-existing hydronephrosis and development of new hydronephrosis.","authors":"Marinka J Remmelink, Nader El Awadly, Berber Arbeel-Weening, Sven Nadorp, Maicle R Leter, Jorg R Oddens, Katharina Brück, Jakko A Nieuwenhuijzen, Adriaan D Bins","doi":"10.1186/s13014-025-02678-9","DOIUrl":"10.1186/s13014-025-02678-9","url":null,"abstract":"<p><strong>Background: </strong>Radical cystectomy is the recommended treatment in muscle-invasive bladder cancer patients with hydronephrosis. However, there is no literature on the impact of chemoradiotherapy on pre-existing hydronephrosis or the development of new hydronephrosis. This study aims to assess the incidence, aetiology, and management of hydronephrosis before and after chemoradiotherapy (CRT).</p><p><strong>Materials and methods: </strong>Retrospective cohort study, including patients with muscle-invasive bladder cancer (MIBC) treated with CRT between 1 January 2014 and 5 December 2022. Patients with urethral urothelial carcinoma and with stage T1 were included if they received total bladder irradiation. Exclusion criteria were renal transplantation, ureteral reimplantation, sequential chemotherapy and radiotherapy, CRT as preoperative treatment, urinary diversion before CRT, transitioning to palliative radiotherapy, and sarcomatoid or signet ring cell carcinoma type. Patients were also excluded if no follow-up data was available. In this period 181 patients received CRT, after applying the exclusion criteria a total of 146 patients were eligible for evaluation. The main outcome was hydronephrosis, defined as any grade of dilatation of the renal pelvis with or without ureter dilatation, identified on any form of imaging.</p><p><strong>Results: </strong>146 patients were included, 27 with pre-existing hydronephrosis before CRT and 119 without. The mean age of the patients was 73 years (Standard deviation (SD): 8.59) and 74% was male. Hydronephrosis in patients with pre-existing hydronephrosis persisted after CRT in 74% (n = 20), with 44% (n = 12) receiving drainage. Of the patients without pre-existing hydronephrosis, 21% (n = 25) developed hydronephrosis, and 52% (n = 13) of the patients that developed hydronephrosis required drainage. Tumour was responsible for pre-existing hydronephrosis in 93% (n = 25) and for hydronephrosis after CRT in 22% (n = 6) with pre-existing hydronephrosis. In patients without pre-existing hydronephrosis, hydronephrosis was caused by a tumour in 11 out of 25 patients.</p><p><strong>Conclusions: </strong>Pre-existing hydronephrosis persists after CRT for MIBC in ~ 75% of patients and ~ 20% of patients without pre-existing hydronephrosis develops hydronephrosis after CRT. Around half of these patients receive drainage. These findings may assist in counselling patients with pre-existing hydronephrosis regarding the potential outcomes following CRT.</p>","PeriodicalId":49639,"journal":{"name":"Radiation Oncology","volume":"20 1","pages":"104"},"PeriodicalIF":3.3,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing stereotactic ablative body radiotherapy for ultra-central lung lesions: a comparative dosimetric analysis.","authors":"Dan Tao, Lisi Sun, Lulu Wang, Lina Yang, Wei Zhou, Xiumei Tian, Xianfeng Liu","doi":"10.1186/s13014-025-02675-y","DOIUrl":"10.1186/s13014-025-02675-y","url":null,"abstract":"","PeriodicalId":49639,"journal":{"name":"Radiation Oncology","volume":"20 1","pages":"103"},"PeriodicalIF":3.3,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12175333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk-adapted intensification therapy in high-risk prostate cancer: how relevant is the role of radiation dose.","authors":"A Zapatero, M Roch, C Martín de Vidales, P Castro, N Montes, A Cruz Conde, Laura Fernández-Banda, Laura Zaragoza, Sara Carroceda, F García Vicente","doi":"10.1186/s13014-025-02665-0","DOIUrl":"10.1186/s13014-025-02665-0","url":null,"abstract":"<p><strong>Background/purpose: </strong>Dose escalation has demonstrated a significant improvement in biochemical recurrence in high-risk prostate cancer (HRPCa). We evaluated the impact on overall survival (OS) of dose intensification with external beam radiation therapy (EBRT) in a cohort of HRPCa patients treated in a single institution.</p><p><strong>Methods and materials: </strong>Between January 1997 and January 2024, a total of 1451 consecutive localized PCa patients were treated with primary EBRT alone as part of a prospective institutional program for risk-adapted dose-intensification radiotherapy. For the present analysis, we specifically selected a cohort of 424 consecutive HRPCa patients with a minimum follow-up (FU) of 5 years. The median RT dose was 79.2 Gy (interquartile range [IQR] 74.9-80.3). Short and long-term hormones were administered in 56 (13%) and 350 (83%) of patients respectively. Kaplan-Meier curves were used to calculate overall survival (OS). Cumulative incidence of distant metastasis (DM), and cause specific survival (CSS) were estimated using competing risk regression.</p><p><strong>Results: </strong>Median patient age was 69 years (IQR 65-72) and median FU was 118 months (IQR 88.0-135.0). At the time of analysis, 54 of 424 patients (13%) had died. The leading cause of death was cardiovascular disease in 16/54 patients (4%), followed by PCa in 15 patients (3%). At 10 and 15 years, the KM estimated OS rates were 91% (95% CI 87-93) and 71% (95% CI 61-79), respectively. The corresponding rates for MFS were 87% (95% CI 83-90) and 60% (95% CI 49-68), and for CSS were 97% (95% CI 95-99) and 90% (95% CI 49-81), respectively. In multivariate analysis, when adjusted for patient age, T stage, Gleason/ISUP group, PSA and length of hormone-therapy, higher radiation dose remained significantly associated with an improved OS (HR 0.89; 95% CI 0.84-0.94), MFS (HR 0.94; 95% CI 0.90-0.98) and CSS (HR 0.89; 95% CI 0.84-0.94).</p><p><strong>Conclusions: </strong>The present study confirms that radiation dose intensification is paramount in the treatment of HRPCa with independence of duration of ADT.</p>","PeriodicalId":49639,"journal":{"name":"Radiation Oncology","volume":"20 1","pages":"102"},"PeriodicalIF":3.3,"publicationDate":"2025-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12167573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}